Literature DB >> 9536112

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

M Ryan1, G Murphy, E Ryan, L Nilsson, F Shackley, L Gothefors, K Oymar, E Miller, J Storsaeter, K H Mills.   

Abstract

Recent clinical trials have demonstrated that new generation acellular pertussis vaccines can confer protection against whooping cough. However, the mechanism of protective immunity against Bordetella pertussis infection induced by vaccination remains to be defined. We have examined cellular immune responses in children immunized with a range of acellular and whole cell pertussis vaccines. Immunization of children with a potent whole-cell vaccine induced B. pertussis-specific T cells that secreted interferon-gamma (IFN-gamma), but not interleukin-5 (IL-5). In contrast, T cells from children immunized with acellular pertussis vaccines secreted IFN-gamma and/or IL-5 following stimulation with B. pertussis antigens in vitro. These observations suggest that protective immunity conferred by whole-cell vaccines, like natural immunity, is mediated by type 1 T cells, whereas the mechanism of immune protection generated with acellular vaccines may be more heterogeneous, involving T cells that secreted type 1 and type 2 cytokines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536112      PMCID: PMC1364099          DOI: 10.1046/j.1365-2567.1998.00401.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.

Authors:  E Miller; L A Ashworth; K Redhead; C Thornton; P A Waight; T Coleman
Journal:  Vaccine       Date:  1997-01       Impact factor: 3.641

Review 2.  Functional diversity of helper T lymphocytes.

Authors:  A K Abbas; K M Murphy; A Sher
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

3.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.

Authors:  A Barnard; B P Mahon; J Watkins; K Redhead; K H Mills
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

5.  Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.

Authors:  A Cassone; C M Ausiello; F Urbani; R Lande; M Giuliano; A La Sala; A Piscitelli; S Salmaso
Journal:  Arch Pediatr Adolesc Med       Date:  1997-03

6.  Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells.

Authors:  M Ryan; G Murphy; L Gothefors; L Nilsson; J Storsaeter; K H Mills
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

7.  Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells.

Authors:  B P Mahon; M S Ryan; F Griffin; K H Mills
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

Authors:  F Simondon; M P Preziosi; A Yam; C T Kane; L Chabirand; I Iteman; G Sanden; S Mboup; A Hoffenbach; K Knudsen; N Guiso; S Wassilak; M Cadoz
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

9.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

Authors:  D Greco; S Salmaso; P Mastrantonio; M Giuliano; A E Tozzi; A Anemona; M L Ciofi degli Atti; A Giammanco; P Panei; W C Blackwelder; D L Klein; S G Wassilak
Journal:  N Engl J Med       Date:  1996-02-08       Impact factor: 91.245

10.  A placebo-controlled trial of a pertussis-toxoid vaccine.

Authors:  B Trollfors; J Taranger; T Lagergård; L Lind; V Sundh; G Zackrisson; C U Lowe; W Blackwelder; J B Robbins
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

View more
  79 in total

1.  Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.

Authors:  C M Ausiello; R Lande; F Urbani; A la Sala; P Stefanelli; S Salmaso; P Mastrantonio; A Cassone
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults.

Authors:  C L Weingart; W A Keitel; K M Edwards; A A Weiss
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  C L Weingart; P S Mobberley-Schuman; E L Hewlett; M C Gray; A A Weiss
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.

Authors:  E J Ryan; L Nilsson; N Kjellman; L Gothefors; K H Mills
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

7.  Inhibition of murine allergic airway disease by Bordetella pertussis.

Authors:  Young-Suk Kim; Keun-Sang Kwon; Dae-Ki Kim; Il-Whan Choi; Hern-Ku Lee
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

Review 8.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 9.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

10.  Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model.

Authors:  Darren P Ennis; Joseph P Cassidy; Bernard P Mahon
Journal:  Clin Diagn Lab Immunol       Date:  2005-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.